- Home
- DLY vs ORIC Comparison
DLY vs ORIC Comparison
Compare DLY & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLY
- ORIC
- Stock Information
- Founded
- DLY 2019
- ORIC 2014
- Country
- DLY United States
- ORIC United States
- Employees
- DLY N/A
- ORIC N/A
- Industry
- DLY Investment Managers
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- DLY Finance
- ORIC Health Care
- Exchange
- DLY Nasdaq
- ORIC Nasdaq
- Market Cap
- DLY 759.6M
- ORIC 633.7M
- IPO Year
- DLY N/A
- ORIC 2020
- Fundamental
- Price
- DLY $15.85
- ORIC $9.58
- Analyst Decision
- DLY
- ORIC Strong Buy
- Analyst Count
- DLY 0
- ORIC 9
- Target Price
- DLY N/A
- ORIC $18.75
- AVG Volume (30 Days)
- DLY 215.9K
- ORIC 597.6K
- Earning Date
- DLY 01-01-0001
- ORIC 03-10-2025
- Dividend Yield
- DLY 8.93%
- ORIC N/A
- EPS Growth
- DLY N/A
- ORIC N/A
- EPS
- DLY N/A
- ORIC N/A
- Revenue
- DLY N/A
- ORIC N/A
- Revenue This Year
- DLY N/A
- ORIC N/A
- Revenue Next Year
- DLY N/A
- ORIC N/A
- P/E Ratio
- DLY N/A
- ORIC N/A
- Revenue Growth
- DLY N/A
- ORIC N/A
- 52 Week Low
- DLY $13.26
- ORIC $6.33
- 52 Week High
- DLY $15.95
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- DLY 42.87
- ORIC 54.79
- Support Level
- DLY $15.77
- ORIC $7.86
- Resistance Level
- DLY $15.96
- ORIC $11.15
- Average True Range (ATR)
- DLY 0.16
- ORIC 0.72
- MACD
- DLY 0.00
- ORIC 0.23
- Stochastic Oscillator
- DLY 27.38
- ORIC 52.28
About DLY DoubleLine Yield Opportunities Fund of Beneficial Interest
DoubleLine Yield Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to seek a high level of total return, with an emphasis on current income. The company invests in debt securities and other income-producing investments of issuers anywhere in the world, including in emerging markets, and may invest in investments of any credit quality. Its investment portfolio comprises foreign corporate bonds, foreign government bonds, non-agency commercial mortgage-backed obligations, U.S. corporate bonds, collateralized loan obligations, and bank loans among other securities.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.